Implementation of the Inflation Reduction Act of 2022, P.L. 117-169, drug pricing provisions Quality Improvement Program (QIP) in the End Stage Renal Disease (ESRD) prospective payment system (PPS) Issues related to payment in the CY 2024 End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Policy and technical issues related to the Medicare Advantage program and Medicare Part D prescription drug program Center for Medicare and Medicaid Innovation (CMMI) mandatory and voluntary demonstration programs for patients with chronic kidney disease Implementation of Executive Order 13879, Advancing American Kidney Health CMS proposed inclusion of phosphate binders in the End Stage Renal Disease (ESRD) Prospective Payment System (PPS) Implementation of the 21st Century Cures Act of 2016, P.L. 114-255, extension of Medicare Advantage to Medicare ESRD patients Implications of Supreme Court Decision on Marietta v. DaVita on Medicare Secondary Payer (MSP) statute and commercial group health insurance CY 2024 Appropriations for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
MMM - Medicare/Medicaid HCR - Health Issues
136 - Centers For Medicare and Medicaid Services (CMS) 5 - Government Accountability Office (GAO) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 136 - Centers For Medicare and Medicaid Services (CMS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
AKEBIA THERAPEUTICS, INC.
245 First Street, Suite 1100, Cambridge, MA, 02142, US
SARA FROELICH SARA FROELICH